Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Continuous venetoclax monotherapy for untreated or R/R del(17p) CLL led to a median PFS of 28.2 months and median OS of 62.5 months.Subgroup analysis sugge